Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
Journal of Clinical Medicine|June 26, 2025
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis PatientsFabiola Atzeni, Cinzia Rotondo, Cesare Siragusano, et al.
Journal of Clinical Medicine|April 28, 2023
Rheumatoid Arthritis from Easy to Complex Disease: From the "2022 GISEA International Symposium"Simone Perniola, Maria Sole Chimenti, Francesca Romana Spinelli, et al.
Clinical and Experimental Rheumatology|February 6, 2013
Remission in early, aggressive rheumatoid arthritis: a multicentre prospective observational Italian study ARPA (Artrite Reumatoide Precoce Aggressiva)Fulvia Ceccarelli, Carlo Perricone, Francesco Trotta, et al.
Clinical Rheumatology|August 20, 2013
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics registerFlorenzo Iannone, Elisa Gremese, Gaia Gallo, et al.
The Journal of Rheumatology|April 3, 2020
Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics DatabasesMatthew L Thomas, Gavin Shaddick, Rachel Charlton, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registriesVeronica Codullo, Florenzo Iannone, Luigi Sinigaglia, et al.
Clinical Rheumatology|July 16, 2016
Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function abilityFlorenzo Iannone, Lugi Sinigaglia, Ennio Giulio Favalli, et al.
Autoimmunity Reviews|July 17, 2012
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registryFabiola Atzeni, Piercarlo Sarzi-Puttini, Costantino Botsios, et al.
The Journal of Rheumatology|July 6, 2007
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA studyLuana Mancarella, Francesca Bobbio-Pallavicini, Fulvia Ceccarelli, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Pageof 12